Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females, ≥ 18 years of age at the time of signing the informed consent document~2. Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening~   a. Have moderate to severe plaque psoriasis at Screening and Baseline~3. Must meet all laboratory criteria~4. Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of contraception as described by the Study Doctor while on study medication and for at least 28 days after taking the last dose of study medication~5. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex condom or any nonlatex condom NOT made out of natural \[animal\] membrane \[eg, polyurethane\]) while on study medication and for a least 28 days after the last dose of study medication.~Exclusion Criteria:~1. Other than psoriasis, history of any clinically significant (as determined by the Investigator) or other major uncontrolled disease.~   .~2. Pregnant or breast feeding~3. History of allergy to any component of the study drug~4. Hepatitis B surface antigen positive at Screening~5. Anti-hepatitis C antibody positive at Screening~6. Active tuberculosis (TB) or a history of incompletely treated TB~7. Clinically significant abnormality on 12-Lead Electrocardiogram (ECG) at Screening~8. Clinically significant abnormal chest x-ray~9. History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency~10. Active substance abuse or a history of substance abuse within 6 months prior to Screening~11. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening~12. Malignancy or history of malignancy (except for treated \[ie, cured\] basal cell or squamous cell in situ skin carcinomas and treated \[ie, cured\] cervical intraepithelial neoplasia \[CIN\] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years)~13. Psoriasis flare or rebound within 4 weeks prior to Screening~14. Evidence of skin conditions that would interfere with clinical assessments~15. Topical therapy within 2 weeks of randomization~16. Systemic therapy for psoriasis within 4 weeks prior to randomization~17. Use of phototherapy within 4 weeks prior to randomization (ie, Ultraviolet B (UVB), psoralen and ultraviolet A (PUVA)~18. Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to randomization~19. Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization~20. Use of any investigational drug within 4 weeks prior to randomization~21. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources~22. Prior treatment with apremilast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast (Type: ACTIVE_COMPARATOR): Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
- Apremilast 30 mg (Type: ACTIVE_COMPARATOR): Apremilast 30 mg by mouth (PO) twice a day (BID). Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost). At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study. Non-responders or partial responders (PASI response \<75) received additional topical therapies or phototherapy beginning at Week 32.

Based on this trial design, predict the completion outcome and termination type (if applicable).